Meanwhile, EMT confers metastatic and cancer stem cell properties, such as Sox-2, Oct-4, and CD133 to cancer cells and is always correlated with poor clinical outcomes for cancer patients with malignant transformation stage [26,27]. The gene discussed is PROM1; the disease is cancer.